Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05284409
Other study ID # ADP
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date July 1, 2022
Est. completion date September 2022

Study information

Verified date September 2022
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single Shot Spinal anesthesia (SSSA) is associated with considerable perioperative shivering and can be challenging to treat. Some pharmacologic agents like N-methyl d-aspartate receptor antagonists, magnesium sulfate and opioid analgesics have been used for restriction of post-spinal anesthesia shivering. Besides that shivering is poorly understood, the gold standard for the treatment and prevention has not been defined yet. This study is to determine the effect of prophylactic intravenous administration of acetaminophen versus dexamethasone versus pethidine in controlling shivering induced by spinal anesthesia


Description:

Aim of this study is to compare between the prophylactic intravenous administrations of acetaminophen vs dexamethasone vs pethidine regarding the incidence of shivering induced by single shot spinal anesthesia in the orthopedic surgeries of the lower limbs Ethical Considerations: Approval of the research ethical committee of the faculty of medicine, Ain Shams University will be obtained and informed written consents will be taken from all the participants after full clarification of the study and their rights for withdrawal at any time will be assured and their privacy will be guaranteed. The single shot spinal anesthesia technique will be performed by a single experienced anesthetist. Study tools: Bedside Shivering Assessment Scale (BSAS) to indicate the degree of shivering at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Study Interventions: The study will include 108 patients fulfilling the inclusion criteria undergoing orthopedic surgeries of the lower limbs. The patients will be randomized into three equal groups by a computer-generated table of random numbers, each including 36 patients, namely groups A, B, and C according to the drug used as an anti-shivering agent. The assigned medication will be prepared in a color coded 250 ml polypropylene bottle of normal saline. The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over a duration of 15 to 20 minutes, the study drugs will be prepared by the hospital pharmacy and follow-up of the patients will be conducted by the anesthesia residents not involved in any other part of the study. Group A: (control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia. Group B: 36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia. Group C: 36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia. All patients will be assessed preoperatively, and will be instructed to fast for 6 hours. On arrival to the operating theatre, all patients will have an inserted peripheral wide bore IV access (18 G). Anti-stress measures: intravenous pantoprazole 40 mg will be given. I.V. fluids will be preheated to room temperature. Lactated Ringer's solution will be infused at 10 ml/kg over 30 min before spinal anesthesia. The infusion rate will then be modified according to the intraoperative fluid balance. Conventional monitoring including electrocardiogram (ECG), heart rate (HR), non-invasive blood pressure (NIBP) and pulse oximetry (SPO2) will be conducted. Hemodynamic readings (Mean arterial blood pressure (MAP), HR, and SPO2), peripheral and room temperatures will be recorded before the administration of the single shot spinal anesthesia. The operating and recovery rooms temperatures will be maintained at 25°C±1 with approximately 60% humidity. Preoperatively, all of the patients will receive titration of 0.5 mg Midazolam increments on intravenously as an anesthetic adjuvant. Anesthetic equipment and drugs for resuscitation will be kept ready at hand before starting the spinal anesthesia. Supplemental oxygen (6 liter/min) will be administered via a facemask during the operation. The patients in all of the groups will receive SSSA. The blocks will be performed by well trained personnel. The blocks will be performed before administration of the compared medications after obtaining intravenous (IV) access and application of standard ASA monitoring. Under complete aseptic conditions, single shot spinal anesthesia will be instituted at either L3/4 or L4/5 interspaces. 2.8 mL (14 mg) of 0.5% hyperbaric bupivacaine at a rate of 0.2 ml/sec will be injected in the sitting position by an anesthetist who was blind to the study by using 25 gauge Quincke spinal needle. The patient will be placed in the Supine position. The sensory blockade level will be checked in order not to reach the level of T4. Sensory levels will be assessed by pinprick test to determine the peak sensory level and time to two segment regression in minutes. Motor block will be assessed by using Modified Bromage scale (16) (0 = no block 1 = hip block, 2 = hip and knee block, 3 = hip, knee, and ankle block) to determine the time to reach complete motor block and duration of motor blockade (in minutes). The desired motor and sensory block will be Bromage scale 3 and T6, respectively. All of the patients will be covered with one layer of surgical drapes over the chest, thighs, and calves during the operation and one cotton blanket over the entire body after operation. Assessment parameters: HR, MAP, and SPO2 will be recorded using standard non-invasive monitors before intrathecal injection and thereafter at 5, 10, 15, 20 minutes then every 10 minutes to complete 90 minutes from the intrathecal injection. All of the patients will be observed for: Hypotension (defined as a decrease in MAP of more than 20% from baseline or a decrease of the systolic arterial blood pressure below 90 mmHg and baseline MAP will be calculated from three measurements taken in the ward before the operation) will be treated by crystalloid infusion and if necessary ephedrine 5 mg IV will be administered. The amount of ephedrine given in each group will be recorded. Bradycardia will be considered if the heart rate is less than 50 beats/min and will be treated with IV atropine (0.01mg/kg). Pruritus will be assessed by a four-point ordinal scale where zero points to no itching, one points to mild itching, two points to moderate itching, treatment not requested, three points to severe itching, treatment requested. In case of pruritus (45.5 mg intramuscular pheniramine hydrogen maleate) will be given. The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over the duration of 15 to 20 minutes. The level of sedation will be assessed according to a five-point range: [1] alert and oriented, [2] somnolent, [3] closed eyes, arousable on a verbal order, [4] closed eyes, arousable to physical stimuli and [5] closed eyes and patient unarousable to physical stimuli. Body temperature (axillary temperature) will be recorded with a percutaneous thermometer. The ambient temperature will be measured by a wall thermometer. The ambient temperature will be maintained at 25 degree Celsius with constant humidity. Fluid management intraoperatively will be done according to bodyweight of the patient and intra-operative losses. When shivering occurs, it will be graded using Bedside Shivering Assessment Scale (BSAS): 0 - None: No Shivering, 1 - Mild: Shivering localized to neck/thorax, maybe seen only as artifact on ECG or felt by palpation 2 - Moderate: Intermittent involvement of the upper extremities +/- thorax 3 -Severe: Generalized shivering or sustained upper / lower extremity shivering. In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded. Patients will be admitted to the PACU. Patient's satisfaction will be assessed by asking the patient to answer the question, "How would you rate your experience after the operation?" using a 7-point Likert verbal rating scale, and acceptable satisfaction score of the patient will range from 5 to 7 (1 - Extremely dissatisfied, 2 - Dissatisfied, 3 - Somewhat dissatisfied, 4 - Undecided, 5 - Somewhat satisfied, 6 - Satisfied, 7 - Extremely satisfied).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 108
Est. completion date September 2022
Est. primary completion date September 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 55 Years
Eligibility Inclusion Criteria: - American Society of Anesthesiologists physical status (ASA) I or II. - Both sexes. - Age ranging from 20 to 55 years old. - Body weight ranging from 60 to 100 kilograms. - Receiving Single Shot Spinal anesthesia. - Scheduled for orthopedic surgeries of the lower limb. Exclusion Criteria: - Patient's refusal. - Allergy to local anesthetics or any of the studied drugs. - Patients with significant cognitive dysfunction. - Duration of surgery more than 120 min. - Patients with hypo- or hyperthyroidism. - An initial body temperature >38.0 or <36.0 degree Celsius. - Receiving vasodilators, or medications likely to alter thermoregulation. - Pregnancy. - Sensory blockade level reaching T4 or higher. - Obesity (BMI > 35 kg/m2).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pethidine
36 patients will receive 0.5 mg/kg Pethidine IVI
Acetaminophen
36 patients will receive 15 mg/kg Acetaminophen IVI
Dexamethasone
36 patients will receive 0.1 mg/kg Dexamethasone IVI

Locations

Country Name City State
Egypt Ain Shams University Hospitals Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of shivering The incidence of shivering induced by single shot spinal anesthesia after the prophylactic administration of the study medications.
When shivering occurs, it will be graded using Bedside Shivering Assessment Scale (BSAS): 0 - None: No Shivering, 1 - Mild: Shivering localized to neck/thorax, maybe seen only as artifact on ECG or felt by palpation 2 - Moderate: Intermittent involvement of the upper extremities +/- thorax 3 -Severe: Generalized shivering or sustained upper / lower extremity shivering.
In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded.
During procedure to up to one hour at the post-anesthesia care unit (PACU)
Secondary The need to administer pethidine In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered. The time of administration of pethidine
Secondary the total dose of Pethidine given In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded. The time of administration of pethidine
Secondary The patient's satisfaction Patient's satisfaction will be assessed by asking the patient to answer the question, "How would you rate your experience after the operation?" using a 7-point Likert verbal rating scale, and acceptable satisfaction score of the patient will range from 5 to 7 (1 - Extremely dissatisfied, 2 - Dissatisfied, 3 - Somewhat dissatisfied, 4 - Undecided, 5 - Somewhat satisfied, 6 - Satisfied, 7 - Extremely satisfied). up to one hour postoperative
Secondary The level of sedation The level of sedation will be assessed according to a five-point range: [1] alert and oriented, [2] somnolent, [3] closed eyes, arousable on a verbal order, [4] closed eyes, arousable to physical stimuli and [5] closed eyes and patient unarousable to physical stimuli. within 5 minutes after the administration of sedative
Secondary Pruritus Severity of pruritus. Pruritus will be assessed by a four-point ordinal scale where zero points to no itching, one points to mild itching, two points to moderate itching, treatment not requested, three points to severe itching, treatment requested. during procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04730609 - Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery Phase 4
Completed NCT02141412 - Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia Phase 4
Not yet recruiting NCT06283771 - The Effect of Heated Socks Developed With Wearable Technology on Hypothermia, Thermal Comfort Perception and Shivering N/A
Completed NCT02436174 - Assessment Of Shivering With iSeismograph N/A
Completed NCT03302351 - Dexmedetomidine, Ketamine and Dexmetedomidine-Ketamine Combination for Control of Shivering During Regional Anaethesia Phase 4
Completed NCT03721432 - The Effect of Oral Pregabalin on Epidural-induced Shivering and Epidural Characteristics N/A
Not yet recruiting NCT03530007 - Anti-shivering Effect of Ondansetron Phase 2/Phase 3
Completed NCT03679065 - Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering Phase 4
Completed NCT03679052 - Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering Phase 4
Completed NCT03675555 - Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering Phase 4
Recruiting NCT04938219 - Shivering_Basel_Baden N/A
Recruiting NCT03157648 - Relationship Between Core-peripheral Temperature Difference and Shivering Symptom in Patients in PACU N/A
Terminated NCT03497507 - Investigating the Effect of Acupressure on Shivering During a Cesarean Delivery in Women Who Were Previously Laboring With an Epidural N/A
Completed NCT03370562 - Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering N/A
Completed NCT05110469 - Comparison of MgSO4 Versus Meperidine for Prevention of Shivering During Spinal Anesthesia Phase 4
Not yet recruiting NCT03566628 - Post-anaesthetic Shivering Amongst Patients Undergoing Cerebral Angiography N/A
Completed NCT02967601 - Influence of Preoperative Anxiety on Shivering During Elective Caesarean Section Under Spinal Anaesthesia N/A
Recruiting NCT05765162 - Safe Brain Initiative, Operationalizing Precision Anaesthesia
Recruiting NCT04870541 - Nefopam Versus Ondansteron for Prevention of Post Spinal Shivering. Phase 4
Active, not recruiting NCT01669213 - Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension N/A